tbResList Print — CRAN Cranberry

Filters: qv=522, qv2=%, rfv=%

Product

CRAN Cranberry
Description:
<p><b>Cranberry (Vaccinium macrocarpon)</b> — A polyphenol-rich edible berry native to North America, classified as a food source and botanical nutraceutical rather than a single therapeutic compound. Common abbreviation: CRAN. Major constituents include A-type proanthocyanidins (PACs), anthocyanins, quercetin and myricetin glycosides, phenolic acids, and triterpenoids such as ursolic acid. Cranberry is best established for reducing recurrent urinary tract infection (UTI) risk through bacterial anti-adhesion activity. Its potential anticancer properties involve antiproliferative, pro-apoptotic, and anti-inflammatory effects, predominantly demonstrated with concentrated extracts or isolated fractions in preclinical models.</p>

<p><b>Primary mechanisms (ranked):</b></p>
<ol>
<li><b>Bacterial adhesion inhibition:</b> A-type proanthocyanidins and cranberry-derived metabolites interfere with uropathogenic Escherichia coli attachment to urinary epithelial surfaces, reducing bacterial colonization potential.</li>
<li><b>PI3K/AKT/mTOR suppression:</b> ↓ PI3K/AKT/mTOR survival signaling and ↓ proliferation in susceptible cancer models (extract-dependent; preclinical).</li>
<li><b>Apoptosis induction:</b> ↑ programmed cell death, including mitochondrial apoptotic signaling and caspase activation in responsive cancer cells (model-dependent).</li>
<li><b>MAPK and cell-cycle regulation:</b> Modulation of ERK, JNK, p38, and cell-cycle regulators, contributing to growth arrest or apoptosis (model-dependent).</li>
<li><b>Inflammatory signaling modulation:</b> ↓ NF-κB-associated inflammatory activity, inflammatory mediators, and selected cytokine responses in experimental systems.</li>
<li><b>Oxidative stress modulation:</b> Antioxidant activity and modulation of cellular ROS responses; direction depends on compound fraction, concentration, and cellular context. NRF2 involvement is secondary and model-dependent.</li>
<li><b>Migration and invasion inhibition:</b> ↓ cancer cell migration, adhesion, and selected invasion-associated signaling in preclinical models.</li>
<li><b>Gut microbial metabolism:</b> Transformation of cranberry polyphenols into smaller bioactive phenolic metabolites that may contribute to systemic and urinary biological effects.</li>
</ol>

<p><b>Bioavailability / PK relevance:</b> High-molecular-weight PACs undergo limited intact systemic absorption. Cranberry polyphenols are metabolized extensively by intestinal microbiota and host conjugation pathways, producing circulating and urinary phenolic acids, sulfates, glucuronides, and related metabolites. Plasma exposure is highly variable between individuals. Extract composition, PAC structure, processing, and analytical standardization strongly influence biological activity.</p>

<p><b>In-vitro vs systemic exposure relevance:</b> Many antiproliferative experiments use concentrated cranberry extracts or isolated PAC fractions at levels unlikely to be reproduced systemically after ordinary dietary intake. Parent PAC exposure is especially limited. Systemic anticancer mechanisms therefore remain pharmacokinetically uncertain, whereas urinary tract anti-adhesion mechanisms are more directly compatible with demonstrated clinical activity and urinary exposure to cranberry-derived compounds.</p>

<p><b>Clinical evidence status:</b> RCT/meta-analysis evidence supports reduced recurrent UTI risk in selected populations, especially women with recurrent infections and children. Evidence does not establish cranberry as treatment for active UTI. Cancer evidence remains predominantly preclinical, without established clinical anticancer efficacy, validated oncology dose, or approved cancer-treatment indication. Cranberry is a potential preventive dietary adjunct, not a substitute for antimicrobial or oncological treatment.</p>



<h3>Cranberry — Mechanistic Effects</h3>
<table>
<thead>
<tr>
<th>Rank</th>
<th>Pathway / Axis</th>
<th>Cancer Cells</th>
<th>Normal Cells</th>
<th>TSF</th>
<th>Primary Effect</th>
<th>Notes / Interpretation</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Bacterial Adhesion / Uropathogenic E. coli</td>
<td>Not established</td>
<td>↓ bacterial attachment to urothelial cells</td>
<td>R/G</td>
<td>Reduced urinary tract bacterial colonization</td>
<td>Principal clinically relevant mechanism. A-type PACs and cranberry-derived urinary metabolites contribute to anti-adhesion activity. Human RCT evidence supports prevention in selected populations, not treatment of active infection.</td>
</tr>
<tr>
<td>2</td>
<td>PI3K / AKT / mTOR</td>
<td>↓ pathway activation</td>
<td>↔ / context-dependent</td>
<td>R/G</td>
<td>↓ proliferation and survival signaling</td>
<td>Demonstrated with purified cranberry PACs in esophageal and other cancer models. Oral PAC exposure and clinical translation remain uncertain.</td>
</tr>
<tr>
<td>3</td>
<td>Apoptosis / Autophagy / Cell Death</td>
<td>↑ cell death; mechanism varies</td>
<td>↔ / context-dependent</td>
<td>G</td>
<td>Reduced tumor cell viability</td>
<td>Caspase-independent death, autophagy-associated effects, apoptosis, and necrosis have been reported depending on cell model. Apoptosis is not the universal dominant mechanism.</td>
</tr>
<tr>
<td>4</td>
<td>MAPK / ERK / JNK / p38</td>
<td>↑ / ↓ context-dependent</td>
<td>↔ / context-dependent</td>
<td>R/G</td>
<td>Growth and stress-response modulation</td>
<td>Different PAC preparations and cancer models exhibit distinct MAPK responses.</td>
</tr>
<tr>
<td>5</td>
<td>Cell Cycle / G2-M Arrest</td>
<td>↑ cell-cycle arrest</td>
<td>Uncertain</td>
<td>G</td>
<td>↓ cellular proliferation</td>
<td>G2-M arrest reported in esophageal adenocarcinoma models using concentrated PAC fractions.</td>
</tr>
<tr>
<td>6</td>
<td>NF-κB / Inflammatory Signaling</td>
<td>↓ inflammatory signaling (model-dependent)</td>
<td>↓ excessive inflammatory activation</td>
<td>R/G</td>
<td>Anti-inflammatory effects</td>
<td>Reported in experimental inflammatory and cancer systems. Effects vary with extract composition and cellular context.</td>
</tr>
<tr>
<td>7</td>
<td>ROS / Oxidative Stress</td>
<td>↑ / ↓ context-dependent</td>
<td>↓ oxidative stress in some models</td>
<td>P/R</td>
<td>Redox modulation</td>
<td>Direct antioxidant chemistry and cellular redox effects are preparation- and concentration-dependent. Selective pro-oxidant cancer activity is not clinically established.</td>
</tr>
<tr>
<td>8</td>
<td>Mitochondrial Apoptotic Signaling</td>
<td>↑ BAX / BAK-associated death signaling</td>
<td>Uncertain</td>
<td>R/G</td>
<td>Promotion of cancer cell death</td>
<td>Cytochrome c, BAX, BAK, and BCL-family alterations have been observed, but canonical mitochondrial apoptosis is not consistent across models.</td>
</tr>
<tr>
<td>9</td>
<td>Migration / Invasion / Adhesion</td>
<td>↓ migration and invasion in selected models</td>
<td>Uncertain</td>
<td>G</td>
<td>Potential suppression of metastatic phenotypes</td>
<td>Preclinical effects; no demonstrated clinical reduction in metastasis.</td>
</tr>
<tr>
<td>10</td>
<td>NRF2 / Antioxidant Response</td>
<td>↔ / context-dependent</td>
<td>↑ cytoprotective signaling in selected models</td>
<td>R/G</td>
<td>Secondary stress-response modulation</td>
<td>Not an established dominant mechanism of cranberry anticancer activity. NRF2 activation can have different consequences in normal and malignant cells.</td>
</tr>
<tr>
<td>11</td>
<td>Chemosensitization</td>
<td>↑ sensitivity in selected experimental models</td>
<td>Uncertain</td>
<td>G</td>
<td>Potential enhancement of cytotoxic treatments</td>
<td>Preclinical only. No validated cranberry-based chemotherapy combination or clinical dose.</td>
</tr>
<tr>
<td>12</td>
<td>Clinical Translation Constraint</td>
<td>High extract exposure commonly required</td>
<td>Generally well tolerated orally</td>
<td>G</td>
<td>Limited systemic anticancer translation</td>
<td>Poor intact PAC absorption; extensive microbial metabolism; variable extract standardization. Cancer efficacy unproven. High intake may cause gastrointestinal effects; potential warfarin interaction and kidney-stone considerations warrant caution.</td>
</tr>
</tbody>
</table>
<p>TSF: P: 0–30 min R: 30 min–3 hr G: &gt;3 hr</p>




Pathway results for Effect on Cancer / Diseased Cells

Redox & Oxidative Stress(tgid=1) ⓘ

H2O2↑, 1,   lipid-P↓, 1,   ROS↝, 1,   ROS↓, 1,   ROS↑, 1,  

Cell Death(tgid=5) ⓘ

Apoptosis↑, 1,   BAX↑, 1,   Bcl-xL↑, 1,   Casp↑, 1,   Cyt‑c↑, 1,   necrosis↑, 2,   TumCD↑, 1,  

Kinase & Signal Transduction(tgid=6) ⓘ

Akt↓, 2,   mTOR↓, 2,   PI3K↓, 2,  

Transcription & Epigenetics(tgid=7) ⓘ

tumCV↓, 1,  

Autophagy & Lysosomes(tgid=9) ⓘ

TumAuto↑, 2,  

DNA Damage & Repair(tgid=10) ⓘ

PARP↑, 1,  

Cell Cycle & Senescence(tgid=11) ⓘ

TumCCA↑, 1,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

TumCG↓, 1,   TumCP↓, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

IL6↓, 1,   TNF-α↓, 1,  

Clinical Biomarkers(tgid=22) ⓘ

IL6↓, 1,  

Functional Outcomes(tgid=23) ⓘ

AntiCan↑, 1,   toxicity↓, 1,  

Ingredients & Constituents(tgid=25) ⓘ

Ingr↝, 1,  
Total Targets: 27

Pathway results for Effect on Normal Cells

Transcription & Epigenetics(tgid=7) ⓘ

other↝, 2,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↝, 2,   Dose?, 1,   eff↓, 1,   eff∅, 1,   eff↝, 1,  

Functional Outcomes(tgid=23) ⓘ

Risk↓, 1,  

Ingredients & Constituents(tgid=25) ⓘ

Ingr↝, 1,  
Total Targets: 8

Research papers

Year Title Authors PMID Link Flag
2023Cranberries for preventing urinary tract infectionsWilliams G—https://www.cochrane.org/evidence/CD001321_cranberries-preventing-urinary-tract-infections0
2021Safety of Cranberry: Evaluation of Evidence of Kidney Stone Formation and Botanical Drug-InteractionsEmily Madden34015833https://pubmed.ncbi.nlm.nih.gov/34015833/0
2017Absorption, Metabolism and Excretion of Cranberry (Poly)phenols in Humans: A Dose Response Study and Assessment of Inter-Individual VariabilityRodrigo P FelicianoPMC5372931https://pmc.ncbi.nlm.nih.gov/articles/PMC5372931/0
2016Cranberries and Cancer: An Update of Preclinical Studies Evaluating the Cancer Inhibitory Potential of Cranberry and Cranberry Derived ConstituentsKatherine M WehPMC5039576https://pmc.ncbi.nlm.nih.gov/articles/PMC5039576/0
2015Cranberry proanthocyanidins inhibit esophageal adenocarcinoma in vitro and in vivo through pleiotropic cell death induction and PI3K/AKT/mTOR inactivationLaura A KrestyPMC4741777https://pmc.ncbi.nlm.nih.gov/articles/PMC4741777/0